Upgrade to SI Premium - Free Trial

H.C. Wainwright Reiterates Buy Rating on Intellia Therapeutics (NTLA)

September 9, 2026 7:29 AM
H.C. Wainwright analyst Mitchell S. Kapoor reiterated a Buy rating and $25.00 price target on Intellia Therapeutics (NASDAQ: NTLA).The analyst ...

(Premium-only article. Please sign in or upgrade to SI Premium to view.)

Categories

Analyst Comments